PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM

Perampanel (PER) is a novel drug for treatment of refractory partial epilepsy in patients≥12 y.o. with proven efficacy and safety. PER is registered and may also be used successfully as adjunctive treatment in therapy of primary generalized tonic-clonic seizures (PGTCS).Objective. To determine the e...

Full description

Bibliographic Details

Published in:	Фармакоэкономика
Main Authors:	N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2017-05-01
Subjects:	refractory partial onset epilepsy tonic-clonic seizures perampanel adjuvant therapy adverse event direct costs pharmacoeconomics pharmacoeconomic modeling
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/180